Effects of Baduanjin on gait parameters and serum nerve growth factor in Parkinson disease patients with freezing of gait
Objective To explore the effect of Baduanjin on gait parameters and serum nerve growth factor in Parkinson disease(PD)patients with freezing of gait(FOG).Methods From December 2021 to December 2022,thirty-eight PD patients with FOG who met the inclusion and exclusion criteria were randomly divided into observation group(n=18)and control group(n=20)by random number table.The patients in both two groups received 4 weeks of drug therapy combined with basic rehabilitation treatment re-spectively,and the patients in observation group received additional Baduanjin training.Efficacy was evalua-ted 1 day before intervention and after 4 weeks of intervention through unified Parkinson's disease rating scale-Ⅱ(UPDRS-Ⅱ)item 14,freezing of gait questionnaire(FOGQ),gait starting time,gait cycle,stride length,dynamic plantar peak pressure and average pressure,while the levels of brain-derived neurotrophic factor(BDNF)and glial cell line-derived neurotrophic factor(GDNF)in peripheral blood of patients were tested.SPSS 23.0 software was used to conduct Chi-square test,paired t-test,independent sample t-test and Mann-Whitney U test.Results Before treatment,there were no significant differences in score of UPDRS-Ⅱ item 14,FOGQ score,gait starting time,gait cycle,stride length,dynamic planar peak pressure,average pressure,peripheral blood BDNF level and GDNF level between the two groups(t=-0.542,0.562,0.490,0.674,0.440,0.606,-0.835,-0.873,-0.250,all P＞0.05).After treatment,compared with the control group,dynamic plantar peak pressure(control group(14.26±3.23)N/cm2,observation group(11.40±4.13)N/cm2,t=-2.389,P=0.022)and plantar average pressure(control group(3.34± 0.72)N/cm2,observation group(2.79±0.81)N/cm2,t=-2.209,P=0.034)of the observation group were significantly decreased(both P＜0.05).There were no significant differences in UPDRS-Ⅱ item 14,FOGQ score,gait starting time,gait cycle,stride length,BDNF and GDNF concentrations in peripheral blood between the two groups after treatment(all P＞0.05).The difference between pre-treatment and post-treat-ment of FOGQ score(control group 1.00(0.00,1.00),observation group 2.00(0.75,3.00),Z=-2.547,P=0.011),gait starting time(control group-1.04(-1.86,-0.47)s,observation group-2.34(-3.41,-1.03)s,Z=-2.280,P=0.023),gait cycle(control group 0.29(0.08,0.58)s,observation group 0.35(0.16,1.00)s,Z=-2.748,P=0.006),stride length(control group 0.19(0.14,0.24)m,ob-servation group 0.26(0.23,0.38)m,Z=-1.360,P=0.005),the dynamic plantar peak pressure(control group-4.11(-5.87,-2.57)N/cm2,observation group-8.44(-10.12,-4.81)N/cm2,Z=-3.333,P=0.001)and average pressure(control group-0.55(-1.00,-0.03)N/cm2,observation group-1.11(-1.51,-0.66)N/cm2,Z=-2.062,P=0.009)in the observation group were better than those in the con-trol group.After treatment,the BDNF level in peripheral blood in observation group was higher than before treatment(t=-2.315,P=0.033).Conclusion Baduanjin can improve frozen gait score and gait parameters in PD patients with FOG,which may be related to the increase of peripheral blood BDNF.
Parkinson diseaseBaduanjinFreezing of gaitBrain-derived neurotrophic fac-torGlial cell line-derived neurotrophic factor
NETL
NSTL
万方数据
